|
In March 2006 Aurelium BioPharma signed a collaboration/semi-exclusive out-licensing agreement with BioSite (San Diego, CA) allowing BioSite to use a subset of Aurelium’s cancer biomarker panel to develop a blood-based diagnostic for early detection of breast cancer.
|
|
|